title: Proteomic and functional investigation of the colon cancer relapse-associated genes NOX4 and ITGA3.
abstract: Colon cancer is a major cause of cancer-related deaths worldwide. Adjuvant chemotherapy significantly reduces mortality in stage III colon cancer; however, it is only marginally effective in stage II patients. There is also increasing evidence that right-side colon cancer is different from left-side colon cancer. We have observed that the genes altered in expression between the poor and good prognosis tumors vary significantly depending on whether the malignancy originates on the right or left side of the colon. We have identified NADPH oxidase 4 (NOX4) to be highly predictive of relapse in stage II left-side colon cancer, whereas integrin alpha 3 beta 1 (ITGA3) is predictive of relapse in stage II right-side colon cancer. To investigate the underlying molecular mechanisms, we are analyzing the effect of ITGA3 and NOX4 silencing via RNA interference and pharmacological inhibition on global protein expression patterns via iTRAQ labeling and mass spectrometry in colon cancer cells. On the basis of bioinformatic analysis, the functions of these genes were assessed through phenotypic assays, revealing roles in cell migration and reactive oxygen species generation. These biomarkers for relapse risk are of clinical interest and lead to insight into how a tumor progresses to metastasis.
authors.affiliation: Harper Cancer Research Institute, ‡Department of Chemistry & Biochemistry, and §Department of Applied and Computational Mathematics and Statistics, University of Notre Dame , Notre Dame, Indiana 46556, United States.
authors.forename: Kerry M
authors.initials: KM
authors.lastname: Bauer
authors.forename: Tanya N
authors.initials: TN
authors.lastname: Watts
authors.forename: Steven
authors.initials: S
authors.lastname: Buechler
authors.forename: Amanda B
authors.initials: AB
authors.lastname: Hummon
mesh_terms: D003110:Colonic Neoplasms / Q000235:genetics* / Q000503:physiopathology*; D019295:Computational Biology; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics / Q000502:physiology*; D006801:Humans; D039201:Integrin alpha3beta1 / Q000235:genetics*; D013058:Mass Spectrometry; D000074663:NADPH Oxidase 4; D019255:NADPH Oxidases / Q000235:genetics*; D010641:Phenotype; D011379:Prognosis; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D012008:Recurrence
chemical_list: D039201:Integrin alpha3beta1; D034741:RNA, Small Interfering; D000074663:NADPH Oxidase 4; D019255:NADPH Oxidases; C498910:NOX4 protein, human
keywords: ITGA3; NOX4; Q-Exactive; colon cancer; iTRAQ
references.citation: J Cell Sci. 2004 Aug 15;117(Pt 18):4043-54
references.pmid: 15280429
references.citation: Carcinogenesis. 2008 Jan;29(1):2-8
references.pmid: 17916902
references.citation: Cancer. 2008 Mar 15;112(6):1272-81
references.pmid: 18224668
references.citation: BMJ. 2002 Apr 20;324(7343):931-2
references.pmid: 11964327
references.citation: Free Radic Res. 2009 Jun;43(6):523-32
references.pmid: 19431059
references.citation: Wound Repair Regen. 2010 May-Jun;18(3):325-34
references.pmid: 20412552
references.citation: Cell Adh Migr. 2011 Mar-Apr;5(2):199-206
references.pmid: 21343695
references.citation: Mol Carcinog. 2012 May;51(5):411-21
references.pmid: 21656576
references.citation: Cancer Sci. 2008 May;99(5):879-87
references.pmid: 18294287
references.citation: Mutat Res. 2012 Oct-Dec;751(2):77-81
references.pmid: 22580379
references.citation: Cell Mol Life Sci. 2012 Jul;69(14):2327-43
references.pmid: 22648375
references.citation: Oncogenesis. 2013 Sep 16;2:e71
references.pmid: 24042735
references.citation: Int J Cancer. 2002 Oct 10;101(5):403-8
references.pmid: 12216066
references.citation: J Mol Diagn. 2006 May;8(2):193-201
references.pmid: 16645205
references.citation: Biochem Pharmacol. 2013 Jul 15;86(2):253-66
references.pmid: 23688500
references.citation: BMC Urol. 2011 Oct 28;11:22
references.pmid: 22032647
references.citation: Eur J Cancer. 2004 Jul;40(10):1593-8
references.pmid: 15196545
references.citation: Oncogene. 1995 Jan 5;10(1):33-7
references.pmid: 7824277
references.citation: Cancer Biol Ther. 2010 Aug 1;10(3):223-31
references.pmid: 20523116
references.citation: Cell Mol Life Sci. 2012 Jul;69(14):2435-42
references.pmid: 22581366
references.citation: Ann Intern Med. 1990 Nov 15;113(10):779-88
references.pmid: 2240880
references.citation: J Biomed Sci. 2011 Feb 07;18:12
references.pmid: 21299869
references.citation: Cell Mol Life Sci. 2012 Sep;69(18):3159-60
references.pmid: 22875281
references.citation: Mol Cell Proteomics. 2011 Oct;10(10):M110.005397
references.pmid: 21622897
references.citation: Genes Dev. 2006 Jul 15;20(14):1933-45
references.pmid: 16815997
references.citation: Mod Pathol. 2001 Nov;14(11):1126-32
references.pmid: 11706074
references.citation: Cancer Res. 2009 Mar 15;69(6):2647-54
references.pmid: 19276355
references.citation: Free Radic Biol Med. 2012 Oct 1;53(7):1489-99
references.pmid: 22728268
references.citation: Biotechniques. 2009 Apr;46(4):265-74
references.pmid: 19450233
references.citation: Cell Res. 2007 Apr;17(4):298-300
references.pmid: 17404596
references.citation: Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7
references.pmid: 11416159
references.citation: Cold Spring Harb Perspect Biol. 2011 Sep 01;3(9):a005074
references.pmid: 21885598
references.citation: Mol Biol Cell. 1999 Feb;10(2):259-70
references.pmid: 9950675
references.citation: Free Radic Biol Med. 2002 Nov 15;33(10):1419-32
references.pmid: 12419474
references.citation: Br J Cancer. 2010 Sep 28;103(7):1040-7
references.pmid: 20717118
references.citation: Surg Today. 1998;28(10):1001-6
references.pmid: 9786570
references.citation: Biochim Biophys Acta. 2011 Jun;1807(6):534-42
references.pmid: 20849810
references.citation: J Zhejiang Univ Sci B. 2009 Mar;10(3):219-29
references.pmid: 19283877